Premium
Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan
Author(s) -
Don G.W.,
Joseph F.,
Celermajer D.S.,
Corte T.J.
Publication year - 2012
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.12007
Subject(s) - medicine , bosentan , hepatic dysfunction , liver dysfunction , progressive systemic sclerosis , cardiology , intensive care medicine , endothelin receptor , raynaud disease , receptor
A patient with pulmonary arterial hypertension secondary to systemic sclerosis was successfully treated with sitaxentan prior to its worldwide withdrawal (because of hepatotoxicity concerns), but then ironically experienced acute hepatic dysfunction during substitute bosentan therapy, and was eventually stabilised on a phosphodiesterase‐5 inhibitor.